The Lord of the NanoRings: cyclodextrins and the battle against SARSCoV-2
Making a comparison between CDs and the unique Ring of the legendary novel of The Lord of the Rings, J.
Category: CD as API
Investigation of Cytotoxicity and Cell Uptake of Cationic Beta-Cyclodextrins as Valid Tools in Nasal Delivery
Cyclodextrin polymers have high applicability in pharmaceutical formulations due to better biocompatibility, solubility enhancement, loading capacity and controlled drug release
Clinical trial: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses
Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of
Cyclodextrin nanosponges for organic toxic molecule removal
Chronic Kidney Disease (CKD) is a global health problem that causes serious economic burden for countries and patients, besides having
Cyclodextrin dimers to treat atherosclerotic plaques by targeting various forms of cholesterol
SENS Research Foundation (USA, California) filed a PCT patent application (WO2020142716) that was recently published. In the invention, a new class
Cyclodextrins in first-line defense against COVID-19
Medical press published the news on the research at the University of Southern California (USC) Dr. Allen and Charlotte Ginsburg
Methyl BCD for axon regeneration after injury – PNAS cover paper
The cover paper of PNAS (1) presents a concept for promoting the neuronal regenerative potential by engineering the expression of
Cyclodextrin to prevent abdominal aortic aneurysm
The scientists at University of Michigan Medical Center, Ann Arbor, MI published on a new application of hydroxypropyl beta-cyclodextrin (HPβCD)
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
Underdog Pharmaceuticals Announces MD.USE Partnership and Technology Acquisition
Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed